Tag: 205.08

Carling, Robert W. et al. published their research in Journal of Medicinal Chemistry in 2005 | CAS: 22808-29-3

4-tert-Butyl-3,6-dichloropyridazine (cas: 22808-29-3) belongs to pyridazine derivatives. Pyridazines are rare in nature, possibly reflecting the scarcity of naturally occurring hydrazines, common building blocks for the synthesis of these heterocycles. Pyridazine can act as a hydrogen bond acceptor to improve the physicochemical properties of drug molecules by increasing their water solubility, and has a high affinity for complexing with targets due to its dipole moment.Safety of 4-tert-Butyl-3,6-dichloropyridazine

7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4- triazol-3-ylmethoxy)-3-(2-fluorophenyl)- 1,2,4-triazolo[4,3-b]pyridazine: A Functionally Selective 纬-Aminobutyric AcidA (GABAA) 伪2/伪3-Subtype Selective Agonist That Exhibits Potent Anxiolytic Activity but Is Not Sedating in Animal Models was written by Carling, Robert W.;Madin, Andrew;Guiblin, Alec;Russell, Michael G. N.;Moore, Kevin W.;Mitchinson, Andrew;Sohal, Bindi;Pike, Andrew;Cook, Susan M.;Ragan, Ian C.;McKernan, Ruth M.;Quirk, Kathleen;Ferris, Pushpinder;Marshall, George;Thompson, Sally Ann;Wafford, Keith A.;Dawson, Gerard R.;Atack, John R.;Harrison, Timothy;Castro, Jose L.;Street, Leslie J.. And the article was included in Journal of Medicinal Chemistry in 2005.Safety of 4-tert-Butyl-3,6-dichloropyridazine This article mentions the following:

There is increasing evidence that compounds with selectivity for 纬-aminobutyric acidA (GABAA) 伪2- and/or 伪3-subtypes may retain the desirable anxiolytic activity of nonselective benzodiazepines but possess an improved side effect profile. Herein we describe a novel series of GABAA 伪2/伪3 subtype-selective agonists leading to the identification of the development candidate 17, a nonsedating anxiolytic in preclin. animal assays. In the experiment, the researchers used many compounds, for example, 4-tert-Butyl-3,6-dichloropyridazine (cas: 22808-29-3Safety of 4-tert-Butyl-3,6-dichloropyridazine).

4-tert-Butyl-3,6-dichloropyridazine (cas: 22808-29-3) belongs to pyridazine derivatives. Pyridazines are rare in nature, possibly reflecting the scarcity of naturally occurring hydrazines, common building blocks for the synthesis of these heterocycles. Pyridazine can act as a hydrogen bond acceptor to improve the physicochemical properties of drug molecules by increasing their water solubility, and has a high affinity for complexing with targets due to its dipole moment.Safety of 4-tert-Butyl-3,6-dichloropyridazine

Referemce:
Pyridazine – Wikipedia,
Pyridazine | C4H4N2 – PubChem

 

Fox, Brian M. et al. published their research in Bioorganic & Medicinal Chemistry Letters in 2010 | CAS: 22808-29-3

4-tert-Butyl-3,6-dichloropyridazine (cas: 22808-29-3) belongs to pyridazine derivatives. Pyridazine-based compounds continued to be a great source of biologically active compounds as evidenced by the number of publications which emerged in 2021. Pyridazine and derivatives coordinate readily with transition metals to form complexes and catalysts with synthetic utility.HPLC of Formula: 22808-29-3

Discovery of pyrrolopyridazines as novel DGAT1 inhibitors was written by Fox, Brian M.;Iio, Kiyosei;Li, Kexue;Choi, Rebeka;Inaba, Takashi;Jackson, Simon;Sagawa, Shoichi;Shan, Bei;Tanaka, Masahiro;Yoshida, Atsuhito;Kayser, Frank. And the article was included in Bioorganic & Medicinal Chemistry Letters in 2010.HPLC of Formula: 22808-29-3 This article mentions the following:

A new structural class of DGAT1 inhibitors was discovered and the structure-activity relationship was explored. The pyrrolotriazine core of the original lead mol. was changed to a pyrrolopyridazine core providing an increase in potency. Further exploration resulted in optimization of the Pr group at C7 and the discovery that the ester at C6 could be replaced by five-membered heterocyclic rings. The analogs prepared have DGAT1 IC50 values ranging from >10 渭M to 48 nM. In the experiment, the researchers used many compounds, for example, 4-tert-Butyl-3,6-dichloropyridazine (cas: 22808-29-3HPLC of Formula: 22808-29-3).

4-tert-Butyl-3,6-dichloropyridazine (cas: 22808-29-3) belongs to pyridazine derivatives. Pyridazine-based compounds continued to be a great source of biologically active compounds as evidenced by the number of publications which emerged in 2021. Pyridazine and derivatives coordinate readily with transition metals to form complexes and catalysts with synthetic utility.HPLC of Formula: 22808-29-3

Referemce:
Pyridazine – Wikipedia,
Pyridazine | C4H4N2 – PubChem

 

Carling, Robert W. et al. published their research in Journal of Medicinal Chemistry in 2005 | CAS: 22808-29-3

4-tert-Butyl-3,6-dichloropyridazine (cas: 22808-29-3) belongs to pyridazine derivatives. Pyridazines are rare in nature, possibly reflecting the scarcity of naturally occurring hydrazines, common building blocks for the synthesis of these heterocycles. Pyridazine can act as a hydrogen bond acceptor to improve the physicochemical properties of drug molecules by increasing their water solubility, and has a high affinity for complexing with targets due to its dipole moment.Safety of 4-tert-Butyl-3,6-dichloropyridazine

7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4- triazol-3-ylmethoxy)-3-(2-fluorophenyl)- 1,2,4-triazolo[4,3-b]pyridazine: A Functionally Selective γ-Aminobutyric AcidA (GABAA) α2/α3-Subtype Selective Agonist That Exhibits Potent Anxiolytic Activity but Is Not Sedating in Animal Models was written by Carling, Robert W.;Madin, Andrew;Guiblin, Alec;Russell, Michael G. N.;Moore, Kevin W.;Mitchinson, Andrew;Sohal, Bindi;Pike, Andrew;Cook, Susan M.;Ragan, Ian C.;McKernan, Ruth M.;Quirk, Kathleen;Ferris, Pushpinder;Marshall, George;Thompson, Sally Ann;Wafford, Keith A.;Dawson, Gerard R.;Atack, John R.;Harrison, Timothy;Castro, Jose L.;Street, Leslie J.. And the article was included in Journal of Medicinal Chemistry in 2005.Safety of 4-tert-Butyl-3,6-dichloropyridazine This article mentions the following:

There is increasing evidence that compounds with selectivity for γ-aminobutyric acidA (GABAA) α2- and/or α3-subtypes may retain the desirable anxiolytic activity of nonselective benzodiazepines but possess an improved side effect profile. Herein we describe a novel series of GABAA α2/α3 subtype-selective agonists leading to the identification of the development candidate 17, a nonsedating anxiolytic in preclin. animal assays. In the experiment, the researchers used many compounds, for example, 4-tert-Butyl-3,6-dichloropyridazine (cas: 22808-29-3Safety of 4-tert-Butyl-3,6-dichloropyridazine).

4-tert-Butyl-3,6-dichloropyridazine (cas: 22808-29-3) belongs to pyridazine derivatives. Pyridazines are rare in nature, possibly reflecting the scarcity of naturally occurring hydrazines, common building blocks for the synthesis of these heterocycles. Pyridazine can act as a hydrogen bond acceptor to improve the physicochemical properties of drug molecules by increasing their water solubility, and has a high affinity for complexing with targets due to its dipole moment.Safety of 4-tert-Butyl-3,6-dichloropyridazine

Referemce:
Pyridazine – Wikipedia,
Pyridazine | C4H4N2 – PubChem

 

Fox, Brian M. et al. published their research in Bioorganic & Medicinal Chemistry Letters in 2010 | CAS: 22808-29-3

4-tert-Butyl-3,6-dichloropyridazine (cas: 22808-29-3) belongs to pyridazine derivatives. Pyridazine-based compounds continued to be a great source of biologically active compounds as evidenced by the number of publications which emerged in 2021. Pyridazine and derivatives coordinate readily with transition metals to form complexes and catalysts with synthetic utility.HPLC of Formula: 22808-29-3

Discovery of pyrrolopyridazines as novel DGAT1 inhibitors was written by Fox, Brian M.;Iio, Kiyosei;Li, Kexue;Choi, Rebeka;Inaba, Takashi;Jackson, Simon;Sagawa, Shoichi;Shan, Bei;Tanaka, Masahiro;Yoshida, Atsuhito;Kayser, Frank. And the article was included in Bioorganic & Medicinal Chemistry Letters in 2010.HPLC of Formula: 22808-29-3 This article mentions the following:

A new structural class of DGAT1 inhibitors was discovered and the structure-activity relationship was explored. The pyrrolotriazine core of the original lead mol. was changed to a pyrrolopyridazine core providing an increase in potency. Further exploration resulted in optimization of the Pr group at C7 and the discovery that the ester at C6 could be replaced by five-membered heterocyclic rings. The analogs prepared have DGAT1 IC50 values ranging from >10 μM to 48 nM. In the experiment, the researchers used many compounds, for example, 4-tert-Butyl-3,6-dichloropyridazine (cas: 22808-29-3HPLC of Formula: 22808-29-3).

4-tert-Butyl-3,6-dichloropyridazine (cas: 22808-29-3) belongs to pyridazine derivatives. Pyridazine-based compounds continued to be a great source of biologically active compounds as evidenced by the number of publications which emerged in 2021. Pyridazine and derivatives coordinate readily with transition metals to form complexes and catalysts with synthetic utility.HPLC of Formula: 22808-29-3

Referemce:
Pyridazine – Wikipedia,
Pyridazine | C4H4N2 – PubChem